The Latest Cardiac and Vascular News
CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device that uses AI to help identify […]
In collaboration with iRhythm, Tempus is studying its predictive, AI-enabled algorithmic tests via a network of researchers to determine the impact of detecting patients at increased risk of developing cardiovascular disease CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision […]
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids […]
